ArticleCommunications biology2025
Arsenic promotes ROS-mediated malignant transformation of bronchial epithelial cells by specifically downregulating TXNL1 expression.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Multi-omics integration deciphers arsenic-induced multi-organ toxicity and the novel ferroptosis axis.Toxicology reports · 2026Review
- Distinct Interactions of Arsenite and Cadmium with Metal Homeostasis and the Cellular Stress Response in Human Bronchial Epithelial Cells.International journal of molecular sciences · 2026Article
- The key to arsenic pollution remediation: engineering and functional effects of arsenic-resistant microorganisms.World journal of microbiology & biotechnology · 2026Review
- Article
- TXNL1 in redox and protein quality control: mechanisms and disease relevance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Arsenic exposure is a known cause of lung cancer, primarily mediated through reactive oxygen species (ROS) generation and oxidative DNA damage. However, the precise mechanism by which arsenic modulates ROS levels remains unclear. This study reveals that, contrary to the upregulation of various key ROS scavenging genes, arsenic specifically downregulates the expression of the redox-active protein thioredoxin-like 1 (TXNL1) both in vitro and in vivo. Enhancing TXNL1 expression significantly suppresses arsenic-induced ROS production, DNA oxidative damage, and malignant transformation. Mechanistic investigations indicate that arsenic downregulates TXNL1 expression through the downregulation of the deubiquitinase USP10, which leads to increased ubiquitination and degradation of TXNL1. Additionally, arsenic promotes hypermethylation of the USP10 promoter region by upregulating the expression of DNA methyltransferase 1 (DNMT1), resulting in transcriptional repression of USP10. In summary, our results reveal that arsenic disrupts redox homeostasis via the DNMT1-USP10-TXNL1 axis, identifying a potential target for preventing arsenic-induced lung carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.